Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL906042

CCCn1ncc2ccc(Sc3ccccc3)cc21.N

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 7/20 0.42
▸ HTR2A P28223 4/20 0.40
▸ HTR2C P28335 4/20 0.40
▸ HTR2B P41595 3/20 0.40
▸ CYP1A2 P05177 1/20 0.38
▸ RECQL P46063 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ SLC16A3 O15427 3/20 0.36
▸ SLC16A1 P53985 3/20 0.36
▸ HTR1A P08908 2/20 0.35
▸ ADRA2A P08913 2/20 0.35
▸ ADRA2B P18089 2/20 0.35
▸ ADRA2C P18825 2/20 0.35
▸ HTR1D P28221 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ HTR4 Q13639 1/20 0.35
▸ CNR1 P21554 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL905935 0.84 HTR2A (0.44) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL8007092 0.83 HTR2C (0.48) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL906040 0.79 HTR2A (0.60) KMOHTR2AHTR2CHTR2BHTR1A
Fumaric Acid SCHEMBL8009277 0.77 KMO (0.47) KMOHTR2AHTR2CHTR2BRECQL
SCHEMBL16576448 0.77 HTR2A (0.47) KMOHTR2AHTR2C
SCHEMBL5565705 0.74 CYP1A2 (0.62) KMOCYP1A2RECQLPOLBHSD17B10
SCHEMBL29487638 0.74 CYP1A2 (0.62) KMOCYP1A2RECQLPOLBHSD17B10
Ammonia Solution, Strong SCHEMBL8009916 0.74 HTR2A (0.45) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL20769975 0.72 HTR2A (0.50) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL8430529 0.72 KMO (0.64) KMOHTR2AHTR2CHTR2BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000017170-A2 N1-SUBSTITUTED BENZOPYRAZOLES AS INHIBITORS OF 5-HT2 RECEPTORS VERNALIS RESEARCH LIMITED (GB) 2000-03-30 — — WO claimed
US-20110152272-A1 Treatment Of Incontinence PFIZER INC 2011-06-23 — — US disclosed
EP-2277513-A2 Treatment of incontinence with 5htc2 agonists Pfizer Inc. (US) 2011-01-26 — — EP disclosed
US-20080146583-A1 Treatment of Incontinence PFIZER INC 2008-06-19 — — US disclosed
EP-1620081-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS Pfizer Limited (GB) 2006-02-01 — — EP disclosed
US-20040235856-A1 Treatment of incontinence PFIZER INC 2004-11-25 — — US disclosed
WO-2004096196-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS PFIZER LIMITED (GB) 2004-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235856-A1 Treatment of incontinence HTR2C, HTR5A, ADRA2C KMO 665/4885HTR2A 6/4885HTR2C 1/4885
US-20110152272-A1 Treatment Of Incontinence HTR2C, HTR5A, ADRA2C KMO 665/4885HTR2A 6/4885HTR2C 1/4885
US-20080146583-A1 Treatment of Incontinence HTR2C, HTR5A, ADRA2C KMO 665/4885HTR2A 6/4885HTR2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.